Payment overview · 2025
General Payments
$856.73
28 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffrey Stephen Boyd, PA - C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · UMATILLA, FL · NPI 1023194636
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Stephen Boyd, PA - C received $856.73 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $385.67 | 45.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.08 | 20.8% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.63 | 7.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.02 | 7.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.92 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.21 | 3.5% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $27.53 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.79 | 2.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.02 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.86 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $856.73 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $247.31 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $151.07 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.21 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.49 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.63 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.02 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.92 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 173 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 101 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
173 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
101 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 885 | 295 |
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 194 |
| Lisinopril | Lisinopril | 471 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 132 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 273 | 95 |
| Gabapentin | Gabapentin | 270 | 103 |
| Metformin Hcl | Metformin Hcl | 255 | 84 |
| Losartan Potassium | Losartan Potassium | 245 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 71 |
| Omeprazole | Omeprazole | 200 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 68 |
| Farxiga | Dapagliflozin Propanediol | 173 | 46 |
| Furosemide | Furosemide | 159 | 56 |
| Potassium Chloride | Potassium Chloride | 156 | 62 |
| Valsartan | Valsartan | 145 | 48 |
| Eliquis | Apixaban | 137 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 44 |
| Mounjaro | Tirzepatide | 130 | 23 |
| Jardiance | Empagliflozin | 116 | 34 |
| Trazodone Hcl | Trazodone Hcl | 104 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 39 |
| Prednisone | Prednisone | 100 | 68 |
| Ozempic | Semaglutide | 99 | 20 |
| Tramadol Hcl | Tramadol Hcl | 97 | 32 |
| Allopurinol | Allopurinol | 92 | 24 |
| Famotidine | Famotidine | 88 | 38 |
| Baclofen | Baclofen | 87 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 23 |
| Carvedilol | Carvedilol | 81 | 32 |
| Cephalexin | Cephalexin | 80 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 27 |
| Glimepiride | Glimepiride | 76 | 32 |
| Alendronate Sodium | Alendronate Sodium | 73 | 26 |
| Alprazolam | Alprazolam | 68 | 26 |
| Sertraline Hcl | Sertraline Hcl | 67 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 20 |
| Buspirone Hcl | Buspirone Hcl | 65 | 22 |
| Ibuprofen | Ibuprofen | 62 | 18 |
| Celecoxib | Celecoxib | 61 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 22 |
| Montelukast Sodium | Montelukast Sodium | 59 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 20 |
| Donepezil Hcl | Donepezil Hcl | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 50 | 16 |
| Ezetimibe | Ezetimibe | 46 | 19 |
| Azithromycin | Azithromycin | 45 | 35 |
| Klor-Con 10 | Potassium Chloride | 45 | 16 |
| Bupropion Xl | Bupropion Hcl | 44 | 15 |
| Meloxicam | Meloxicam | 43 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 40 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 16 |
| Mirtazapine | Mirtazapine | 39 | 14 |
| Bumetanide | Bumetanide | 37 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 14 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 36 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 16 |
| Sucralfate | Sucralfate | 34 | 22 |
| Simvastatin | Simvastatin | 33 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 22 |
| Finasteride | Finasteride | 31 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 12 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 17 |
| Mupirocin | Mupirocin | 26 | 22 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 18 |
| Nystatin | Nystatin | 22 | 13 |
| Tadalafil | Tadalafil | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Atenolol | Atenolol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $856.73 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, Kerendia, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, VYNDAQEL, Veltassa | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error